Next Article in Journal
Phleboviruses and the Type I Interferon Response
Next Article in Special Issue
Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure
Previous Article in Journal
PKR Activation Favors Infectious Pancreatic Necrosis Virus Replication in Infected Cells
Previous Article in Special Issue
Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
Article Menu

Export Article

Open AccessReview
Viruses 2016, 8(6), 176; doi:10.3390/v8060176

Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance

1
Center for Vaccinology, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent 9000, Belgium
2
Therapeutic Chemistry Department, National Research Centre (NRC), Dokki, Cairo 12622, Egypt
3
Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Thomas F. Baumert
Received: 23 February 2016 / Revised: 12 May 2016 / Accepted: 16 June 2016 / Published: 22 June 2016
(This article belongs to the Special Issue HCV Drug Resistance)
View Full-Text   |   Download PDF [614 KB, uploaded 22 June 2016]   |  

Abstract

While addition of the first-approved protease inhibitors (PIs), telaprevir and boceprevir, to pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy significantly increased sustained virologic response (SVR) rates, PI-based triple therapy for the treatment of chronic hepatitis C virus (HCV) infection was prone to the emergence of resistant viral variants. Meanwhile, multiple direct acting antiviral agents (DAAs) targeting either the HCV NS3/4A protease, NS5A or NS5B polymerase have been approved and these have varying potencies and distinct propensities to provoke resistance. The pre-clinical in vivo assessment of drug efficacy and resistant variant emergence underwent a great evolution over the last decade. This field had long been hampered by the lack of suitable small animal models that robustly support the entire HCV life cycle. In particular, chimeric mice with humanized livers (humanized mice) and chimpanzees have been instrumental for studying HCV inhibitors and the evolution of drug resistance. In this review, we present the different in vivo HCV infection models and discuss their applicability to assess HCV therapy response and emergence of resistant variants. View Full-Text
Keywords: HCV; animal models; therapy; direct acting antiviral agents; humanized mice; resistance; deep sequencing HCV; animal models; therapy; direct acting antiviral agents; humanized mice; resistance; deep sequencing
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Mesalam, A.A.; Vercauteren, K.; Meuleman, P. Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. Viruses 2016, 8, 176.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top